Advertisement
Extent of baseline burden impacts progression-free and overall survival
Young age, solid tumor, high uptake on PET and KRAS mutation signal risk, suggest need for lobectomy
New review published in Cancers suggests a synergistic benefit
Radiomic nomogram helps clinicians assess risk in patients treated with stereotactic body radiation therapy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Lack of appropriate testing remains a barrier for patients eligible for targeted treatment
Emerging treatment option for patients with advanced disease
Model identifies target OS at which economic benefits of treatment outpace placebo
Largest retrospective study to date confirms randomized trials
Selpercatinib beats others in ORR, PFS, safety
Number of brain metastases doesn’t matter for ALK/EGFR+ patients
Advertisement
Advertisement